CLDX Celldex Therapeutics, Inc.

3.36
0  -1%
Previous Close 3.38
Open 3.40
Price To book 1.53
Market Cap 414.00M
Shares 123,213,000
Volume 765,016
Short Ratio 9.93
Av. Daily Volume 1,878,010

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiated July 2016. Phase 1 dose-escalation portion of the study will complete enrollment by year-end 2017.
CDX-014
Renal cell carcinoma (RCC) - cancer
Phase 2 initiated April 2016. Enrollment to be completed 1Q 2018.
Varlilumab and nivolumab
Solid tumors - cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and atezolizumab (anti-PDL1)
Renal cell carcinoma (RCC) cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and sunitinib (Sutent)
Clear cell renal cell carcinoma (CC-RCC) cancer
Phase 1/2 commenced April 2016
Glembatumumab vedotin
Squamous cell lung cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b enrollment to be completed by the end of September 2017.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data due fall of 2017.
Glembatumumab vedotin, varlilumab, Opdivo or Keytruda
Cancer - melanoma